Neuroimaging-Based Classification Algorithm for Predicting 1p/19q-Codeletion Status in IDH-Mutant Lower Grade Gliomas

References

1. 1.↵
   2. Louis DN,
   3. Perry A,
   4. Reifenberger G, et al

   . The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016;131:803–20 doi:10.1007/s00401-016-1545-1 pmid:27157931

   CrossRefPubMed
2. 2.↵
   2. Appin CL,
   3. Brat DJ

   . Molecular genetics of gliomas. Cancer J 2014;20:66–72 doi:10.1097/PPO.0000000000000020 pmid:24445767

   CrossRefPubMed
3. 3.↵
   2. Yan H,
   3. Parsons DW,
   4. Jin G, et al

   . IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360:765–73 doi:10.1056/NEJMoa0808710 pmid:19228619

   CrossRefPubMedWeb of Science
4. 4.↵
   2. Brat DJ,
   3. Verhaak RG,
   4. Aldape KD, et al

   ; Cancer Genome Atlas Research Network. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 2015;372:2481–98 doi:10.1056/NEJMoa1402121 pmid:26061751

   CrossRefPubMed
5. 5.↵
   2. van den Bent MJ,
   3. Brandes AA,
   4. Taphoorn MJ, et al

   . Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 2013;31:344–50 doi:10.1200/JCO.2012.43.2229 pmid:23071237

   Abstract/FREE Full Text
6. 6.↵
   2. Chamberlain MC,
   3. Born D

   . Prognostic significance of relative 1p/19q codeletion in oligodendroglial tumors. J Neurooncol 2015;125:249–51 doi:10.1007/s11060-015-1906-y pmid:26341371

   CrossRefPubMed
7. 7.↵
   2. van den Bent MJ

   . Chemotherapy for low-grade glioma: when, for whom, which regimen? Curr Opin Neurol 2015;28:633–938 doi:10.1097/WCO.0000000000000257 pmid:26397230

   CrossRefPubMed
8. 8.↵
   2. Zlatescu MC,
   3. TehraniYazdi A,
   4. Sasaki H, et al

   . Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res 2001;61:6713–15 pmid:11559541

   Abstract/FREE Full Text
9. 9.↵
   2. Megyesi JF,
   3. Kachur E,
   4. Lee DH, et al

   . Imaging correlates of molecular signatures in oligodendrogliomas. Clin Cancer Res 2004;10:4303–06 doi:10.1158/1078-0432.CCR-04-0209 pmid:15240515

   Abstract/FREE Full Text
10. 10.↵
    2. Jenkinson MD,
    3. du Plessis DG,
    4. Smith TS, et al

    . Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features. Brain 2006;129(Pt 7):1884–91 doi:10.1093/brain/awl108 pmid:16670176

    CrossRefPubMedWeb of Science
11. 11.↵
    2. Brown R,
    3. Zlatescu M,
    4. Sijben A, et al

    . The use of magnetic resonance imaging to noninvasively detect genetic signatures in oligodendroglioma. Clin Cancer Res 2008;14:2357–62 doi:10.1158/1078-0432.CCR-07-1964 pmid:18413825

    Abstract/FREE Full Text
12. 12.↵
    2. Sherman JH,
    3. Prevedello DM,
    4. Shah L, et al

    . MR imaging characteristics of oligodendroglial tumors with assessment of 1p/19q deletion status. Acta Neurochir (Wien) 2010;152:1827–34 doi:10.1007/s00701-010-0743-1 pmid:20711790

    CrossRefPubMed
13. 13.↵
    2. Kim JW,
    3. Park CK,
    4. Park SH, et al

    . Relationship between radiological characteristics and combined 1p and 19q deletion in World Health Organization grade III oligodendroglial tumours. J Neurol Neurosurg Psychiatry 2011;82:224–27 doi:10.1136/jnnp.2009.178806 pmid:20587495

    Abstract/FREE Full Text
14. 14.↵
    2. Fellah S,
    3. Caudal D,
    4. De Paula AM, et al

    . Multimodal MR imaging (diffusion, perfusion, and spectroscopy): is it possible to distinguish oligodendroglial tumor grade and 1p/19q codeletion in the pretherapeutic diagnosis? AJNR Am J Neuroradiol 2013;34:1326–33 doi:10.3174/ajnr.A3352 pmid:23221948

    Abstract/FREE Full Text
15. 15.↵
    2. Chawla S,
    3. Krejza J,
    4. Vossough A, et al

    . Differentiation between oligodendroglioma genotypes using dynamic susceptibility contrast perfusion-weighted imaging and proton MR spectroscopy. AJNR Am J Neuroradiol 2013;34:1542–49 doi:10.3174/ajnr.A3384 pmid:23370479

    Abstract/FREE Full Text
16. 16.↵
    2. Smits M

    . Imaging of oligodendroglioma. Br J Radiol 2016;89:20150857 doi:10.1259/bjr.20150857 pmid:26849038

    CrossRefPubMed
17. 17.↵
    2. Johnson DR,
    3. Diehn FE,
    4. Giannini C, et al

    . Genetically defined oligodendroglioma is characterized by indistinct tumor borders at MRI. AJNR Am J Neuroradiol 2017;38:678–84 doi:10.3174/ajnr.A5070 pmid:28126746

    Abstract/FREE Full Text
18. 18.↵
    2. Darlix A,
    3. Deverdun J,
    4. Menjot de Champfleur N, et al

    . IDH mutation and 1p19q codeletion distinguish two radiological patterns of diffuse low-grade gliomas. J Neurooncol 2017;133:37–45 doi:10.1007/s11060-017-2421-0 pmid:28434111

    CrossRefPubMed
19. 19.↵
    2. Patel SH,
    3. Poisson LM,
    4. Brat DJ, et al

    . T2-FLAIR mismatch, an imaging biomarker for IDH and 1p/19q status in lower-grade gliomas: a TCGA/TCIA project. Clin Cancer Res 2017;23:6078–85 doi:10.1158/1078-0432.CCR-17-0560 pmid:28751449

    Abstract/FREE Full Text
20. 20.↵
    2. Yoon HJ,
    3. Ahn KJ,
    4. Lee S, et al

    . Differential diagnosis of oligodendroglial and astrocytic tumors using imaging results: the added value of perfusion MR imaging. Neuroradiology 2017;59:665–75 doi:10.1007/s00234-017-1851-x pmid:28550465

    CrossRefPubMed
21. 21.↵
    2. Akkus Z,
    3. Ali I,
    4. Sedlář J, et al

    . Predicting deletion of chromosomal arms 1p/19q in low-grade gliomas from MR images using machine intelligence. J Digit Imaging 2017;30:469–76 doi:10.1007/s10278-017-9984-3 pmid:28600641

    CrossRefPubMed
22. 22.↵
    2. Smits M,
    3. van den Bent MJ

    . Imaging correlates of adult glioma genotypes. Radiology 2017;284:316–31 doi:10.1148/radiol.2017151930 pmid:28723281

    CrossRefPubMed
23. 23.↵
    2. Delfanti RL,
    3. Piccioni DE,
    4. Handwerker J, et al

    . Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status. J Neurooncol 2017;135:601–09 doi:10.1007/s11060-017-2613-7 pmid:28871469

    CrossRefPubMed
24. 24.↵
    2. Park YW,
    3. Han K,
    4. Ahn SS, et al

    . Prediction of IDH1-mutation and 1p/19q-codeletion status using preoperative MR imaging phenotypes in lower grade gliomas. AJNR Am J Neuroradiol 2018;39:37–42 doi:10.3174/ajnr.A5421 pmid:29122763

    Abstract/FREE Full Text
25. 25.↵
    2. Lasocki A,
    3. Gaillard F,
    4. Gorelik A, et al

    . MRI features can predict 1p/19q status in intracranial gliomas. AJNR Am J Neuroradiol 2018;39:687–92 doi:10.3174/ajnr.A5572 pmid:29519793

    Abstract/FREE Full Text
26. 26.↵
    2. Park YW,
    3. Han K,
    4. Ahn SS, et al

    . Whole-tumor histogram and texture analyses of DTI for evaluation of IDH1-mutation and 1p/19q-codeletion status in World Health Organization grade II gliomas. AJNR Am J Neuroradiol 2018;39:693–98 doi:10.3174/ajnr.A5569 pmid:29519794

    Abstract/FREE Full Text
27. 27.↵
    2. Kanazawa T,
    3. Fujiwara H,
    4. Takahashi H, et al

    . H. Imaging scoring systems for preoperative molecular diagnoses of lower-grade gliomas. Neurosurg Rev 2018 Apr 26. [Epub ahead of print] doi:10.1007/s10143-018-0981-x pmid:29700705

    CrossRefPubMed
28. 28.↵
    2. Broen MP,
    3. Smits M,
    4. Wijnenga MM, et al

    . The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation study. Neuro Oncol 2018;20:1393–99 doi:10.1093/neuonc/noy048 pmid:29590424

    CrossRefPubMed
29. 29.↵
    2. Pedano N,
    3. Flanders AE,
    4. Scarpace L, et al

    . Radiology Data from The Cancer Genome Atlas Low Grade (TCGA-LGG) collection. The Cancer Imaging Archive. http://doi.org/10.7937/K9/TCIA.2016.L4LTD3TK. Accessed January 10, 2019.
30. 30.↵
    2. Ceccarelli M,
    3. Barthel FP,
    4. Malta TM, et al

    . Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 2016;164:550–63 doi:10.1016/j.cell.2015.12.028 pmid:26824661

    CrossRefPubMed
31. 31.↵
    2. Capper D,
    3. Weissert S,
    4. Balss J, et al

    . Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 2010;20:245–54 doi:10.1111/j.1750-3639.2009.00352.x pmid:19903171

    CrossRefPubMedWeb of Science
32. 32.↵
    2. Capper D,
    3. Zentgraf H,
    4. Balss J, et al

    . Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 2009;118:599–601 doi:10.1007/s00401-009-0595-z pmid:19798509

    CrossRefPubMedWeb of Science
33. 33.↵
    2. Felsberg J,
    3. Wolter M,
    4. Seul H, et al

    . Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing. Acta Neuropathol 2010;119:501–07 doi:10.1007/s00401-010-0647-4 pmid:20131059

    CrossRefPubMed
34. 34.↵
    2. Youden WJ

    . Index for rating diagnostic tests. Cancer 1950;3:32–35 doi:10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3

    CrossRefPubMedWeb of Science
35. 35.↵
    2. Robin X,
    3. Turck N,
    4. Hainard A, et al

    . pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 2011;12:77 doi:10.1186/1471-2105-12-77 pmid:21414208

    CrossRefPubMed
36. 36.↵
    R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna; R Foundation for Statistical Computing; 2017
37. 37.↵
    2. Qi S,
    3. Yu L,
    4. Li H, et al

    . Isocitrate dehydrogenase mutation is associated with tumor location and magnetic resonance imaging characteristics in astrocytic neoplasms. Oncol Lett 2014;7:1895–902 doi:10.3892/ol.2014.2013 pmid:24932255

    CrossRefPubMed
38. 38.↵
    2. Metellus P,
    3. Coulibaly B,
    4. Colin C, et al

    . Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol 2010;120:719–29 doi:10.1007/s00401-010-0777-8 pmid:21080178

    CrossRefPubMedWeb of Science
39. 39.↵
    2. Choi C,
    3. Ganji SK,
    4. DeBerardinis RJ, et al

    . 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med 2012;18:624–29 doi:10.1038/nm.2682 pmid:22281806

    CrossRefPubMed
40. 40.↵
    2. Chang K,
    3. Bai HX,
    4. Zhou H, et al

    . Residual convolutional neural network for determination of IDH status in low- and high-grade gliomas from MR imaging. Clin Cancer Res 2018;24:1073–81 doi:10.1158/1078-0432.CCR-17-2236 pmid:29167275

    Abstract/FREE Full Text
41. 41.↵
    2. Patel KS,
    3. Carter BS,
    4. Chen CC

    . Role of biopsies in the management of intracranial gliomas. Prog Neurol Surg 2018;30:232–43 doi:10.1159/000464439 pmid:29241178

    CrossRefPubMed
42. 42.↵
    2. Horbinski C,
    3. Miller CR,
    4. Perry A

    . Gone FISHing: clinical lessons learned in brain tumor molecular diagnostics over the last decade. Brain Pathol 2011;21:57–73 doi:10.1111/j.1750-3639.2010.00453.x pmid:21129060

    CrossRefPubMedWeb of Science
43. 43.↵
    2. Riemenschneider MJ,
    3. Jeuken JW,
    4. Wesseling P, et al

    . Molecular diagnostics of gliomas: state of the art. Acta Neuropathol 2010;120:567–84 doi:10.1007/s00401-010-0736-4 pmid:20714900

    CrossRefPubMedWeb of Science